vs
DHI GROUP, INC.（DHX）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
DHI GROUP, INC.的季度营收约是REGENXBIO Inc.的1.0倍（$31.4M vs $30.3M），DHI GROUP, INC.净利率更高（3.0% vs -221.3%，领先224.4%），REGENXBIO Inc.同比增速更快（43.0% vs -9.8%），DHI GROUP, INC.自由现金流更多（$5.7M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -6.7%）
DHI集团是总部位于丹麦的国际水环境企业，业务涵盖水环境软件开发与工程咨询，拥有自主水环境建模软件MIKE Powered by DHI，同时为客户提供商业应用、数据门户、运营服务等全链条水环境解决方案。集团目前在全球设有30个分支机构，在新加坡和丹麦都设有研发中心，全球员工约1050名。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
DHX vs RGNX — 直观对比
营收规模更大
DHX
是对方的1.0倍
$30.3M
营收增速更快
RGNX
高出52.8%
-9.8%
净利率更高
DHX
高出224.4%
-221.3%
自由现金流更多
DHX
多$58.5M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $31.4M | $30.3M |
| 净利润 | $951.0K | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 10.4% | -190.0% |
| 净利率 | 3.0% | -221.3% |
| 营收同比 | -9.8% | 43.0% |
| 净利润同比 | -6.9% | -31.2% |
| 每股收益（稀释后） | $0.03 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DHXRGNX
| Q4 25 | $31.4M | $30.3M | ||
| Q3 25 | $32.1M | $29.7M | ||
| Q2 25 | $32.0M | $21.4M | ||
| Q1 25 | $32.3M | $89.0M | ||
| Q4 24 | $34.8M | $21.2M | ||
| Q3 24 | $35.3M | $24.2M | ||
| Q2 24 | $35.8M | $22.3M | ||
| Q1 24 | $36.0M | $15.6M |
净利润DHXRGNX
| Q4 25 | $951.0K | $-67.1M | ||
| Q3 25 | $-4.3M | $-61.9M | ||
| Q2 25 | $-841.0K | $-70.9M | ||
| Q1 25 | $-9.4M | $6.1M | ||
| Q4 24 | $1.0M | $-51.2M | ||
| Q3 24 | $-200.0K | $-59.6M | ||
| Q2 24 | $943.0K | $-53.0M | ||
| Q1 24 | $-1.5M | $-63.3M |
毛利率DHXRGNX
| Q4 25 | — | — | ||
| Q3 25 | 85.7% | — | ||
| Q2 25 | 84.0% | — | ||
| Q1 25 | 83.4% | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | 85.6% | 48.8% | ||
| Q2 24 | 85.5% | 52.5% | ||
| Q1 24 | 86.5% | 72.6% |
营业利润率DHXRGNX
| Q4 25 | 10.4% | -190.0% | ||
| Q3 25 | -14.0% | -176.3% | ||
| Q2 25 | -3.9% | -296.3% | ||
| Q1 25 | -27.5% | 13.6% | ||
| Q4 24 | 5.0% | -242.1% | ||
| Q3 24 | 1.8% | -256.6% | ||
| Q2 24 | 5.6% | -251.3% | ||
| Q1 24 | 5.5% | -408.8% |
净利率DHXRGNX
| Q4 25 | 3.0% | -221.3% | ||
| Q3 25 | -13.3% | -208.3% | ||
| Q2 25 | -2.6% | -331.8% | ||
| Q1 25 | -28.9% | 6.8% | ||
| Q4 24 | 2.9% | -241.3% | ||
| Q3 24 | -0.6% | -246.3% | ||
| Q2 24 | 2.6% | -237.7% | ||
| Q1 24 | -4.2% | -405.4% |
每股收益（稀释后）DHXRGNX
| Q4 25 | $0.03 | $-1.30 | ||
| Q3 25 | $-0.10 | $-1.20 | ||
| Q2 25 | $-0.02 | $-1.38 | ||
| Q1 25 | $-0.21 | $0.12 | ||
| Q4 24 | $0.02 | $-0.99 | ||
| Q3 24 | $0.00 | $-1.17 | ||
| Q2 24 | $0.02 | $-1.05 | ||
| Q1 24 | $-0.03 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.9M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $94.5M | $102.7M |
| 总资产 | $188.2M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DHXRGNX
| Q4 25 | $2.9M | $230.1M | ||
| Q3 25 | $2.3M | $274.2M | ||
| Q2 25 | $2.8M | $323.3M | ||
| Q1 25 | $2.7M | $267.9M | ||
| Q4 24 | $3.7M | $234.7M | ||
| Q3 24 | $2.1M | $255.5M | ||
| Q2 24 | $3.0M | $290.4M | ||
| Q1 24 | $3.2M | $338.7M |
总债务DHXRGNX
| Q4 25 | — | — | ||
| Q3 25 | $30.0M | — | ||
| Q2 25 | $30.0M | — | ||
| Q1 25 | $33.0M | — | ||
| Q4 24 | $32.0M | — | ||
| Q3 24 | $32.0M | — | ||
| Q2 24 | $35.0M | — | ||
| Q1 24 | $41.0M | — |
股东权益DHXRGNX
| Q4 25 | $94.5M | $102.7M | ||
| Q3 25 | $97.3M | $161.5M | ||
| Q2 25 | $102.5M | $213.7M | ||
| Q1 25 | $103.9M | $274.2M | ||
| Q4 24 | $114.3M | $259.7M | ||
| Q3 24 | $111.3M | $301.4M | ||
| Q2 24 | $109.8M | $348.3M | ||
| Q1 24 | $106.6M | $390.7M |
总资产DHXRGNX
| Q4 25 | $188.2M | $453.0M | ||
| Q3 25 | $192.5M | $525.2M | ||
| Q2 25 | $204.9M | $581.0M | ||
| Q1 25 | $212.1M | $490.9M | ||
| Q4 24 | $221.4M | $466.0M | ||
| Q3 24 | $219.4M | $519.1M | ||
| Q2 24 | $224.4M | $569.4M | ||
| Q1 24 | $231.9M | $629.2M |
负债/权益比DHXRGNX
| Q4 25 | — | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 0.29× | — | ||
| Q1 25 | 0.32× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.29× | — | ||
| Q2 24 | 0.32× | — | ||
| Q1 24 | 0.38× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $5.7M | $-52.8M |
| 自由现金流率自由现金流/营收 | 18.1% | -174.0% |
| 资本支出强度资本支出/营收 | 4.9% | 1.7% |
| 现金转化率经营现金流/净利润 | 7.60× | — |
| 过去12个月自由现金流最近4个季度 | $13.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流DHXRGNX
| Q4 25 | $7.2M | $-52.3M | ||
| Q3 25 | $4.8M | $-56.0M | ||
| Q2 25 | $6.9M | $-49.3M | ||
| Q1 25 | $2.2M | $33.6M | ||
| Q4 24 | $4.4M | $-31.6M | ||
| Q3 24 | $5.5M | $-40.5M | ||
| Q2 24 | $9.1M | $-45.5M | ||
| Q1 24 | $2.1M | $-55.5M |
自由现金流DHXRGNX
| Q4 25 | $5.7M | $-52.8M | ||
| Q3 25 | $3.2M | $-56.5M | ||
| Q2 25 | $4.8M | $-49.7M | ||
| Q1 25 | $88.0K | $32.6M | ||
| Q4 24 | $1.6M | $-32.7M | ||
| Q3 24 | $2.3M | $-40.9M | ||
| Q2 24 | $5.6M | $-46.0M | ||
| Q1 24 | $-2.4M | $-56.0M |
自由现金流率DHXRGNX
| Q4 25 | 18.1% | -174.0% | ||
| Q3 25 | 9.9% | -189.9% | ||
| Q2 25 | 15.1% | -232.8% | ||
| Q1 25 | 0.3% | 36.6% | ||
| Q4 24 | 4.6% | -154.2% | ||
| Q3 24 | 6.5% | -168.9% | ||
| Q2 24 | 15.6% | -206.2% | ||
| Q1 24 | -6.5% | -358.5% |
资本支出强度DHXRGNX
| Q4 25 | 4.9% | 1.7% | ||
| Q3 25 | 5.0% | 1.7% | ||
| Q2 25 | 6.3% | 1.8% | ||
| Q1 25 | 6.7% | 1.2% | ||
| Q4 24 | 8.0% | 5.1% | ||
| Q3 24 | 9.2% | 1.3% | ||
| Q2 24 | 9.7% | 2.1% | ||
| Q1 24 | 12.3% | 3.6% |
现金转化率DHXRGNX
| Q4 25 | 7.60× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | 4.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 9.61× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DHX
| Clearance Jobs | $17.4M | 56% |
| Clearance Jobs Segment | $13.9M | 44% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
